Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) General Information

Description

Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920 gene therapy asset.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Richmond, CA
  • United States
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Acquirer
Corporate Office
  • Richmond, CA
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920)‘s full profile, request access.

Request a free trial

Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920)‘s full profile, request access.

Request a free trial

Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) FAQs

  • Where is Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) headquartered?

    Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) is headquartered in Richmond, CA.

  • What industry is Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) in?

    Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920)’s primary industry is Buildings and Property.

  • Is Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) a private or public company?

    Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) is a Private company.

  • What is the current valuation of Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920)?

    The current valuation of Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) is .

  • What is Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920)’s current revenue?

    The current revenue for Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) is .

  • Who are Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920)’s investors?

    Sangamo Therapeutics has invested in Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920).

  • When was Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) acquired?

    Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) was acquired on 21-Sep-2026.

  • Who acquired Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920)?

    Sangamo Therapeutics (Fabry Disease Program, Isaralgagene Civaparvovec, or ST-920) was acquired by PTC Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process